Skip to main content

Opioid Dependency

3
Pipeline Programs
2
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Indivior
SUBLOCADEApproved
buprenorphine
Indivior
Partial Opioid Agonist [EPC]subcutaneous2017
38M Part D

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Indivior
IndiviorUK - Slough
2 programs
1
1
BuprenorphinePhase 41 trial
Buprenorphine hydrochloride marketed sublingual tabletPhase 21 trial
Active Trials
NCT01075971Completed52Est. Nov 2005
NCT00955162Completed270Est. May 2011
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Psychosocial treatment plus Suboxone pharmacotherapyN/A1 trial
Active Trials
NCT00591617Completed202Est. Dec 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IndiviorBuprenorphine
IndiviorBuprenorphine hydrochloride marketed sublingual tablet
Angeles TherapeuticsPsychosocial treatment plus Suboxone pharmacotherapy

Clinical Trials (3)

Total enrollment: 524 patients across 3 trials

NCT00955162IndiviorBuprenorphine

Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")

Start: Aug 2009Est. completion: May 2011270 patients
Phase 4Completed
NCT01075971IndiviorBuprenorphine hydrochloride marketed sublingual tablet

Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

Start: Sep 2005Est. completion: Nov 200552 patients
Phase 2Completed
NCT00591617Angeles TherapeuticsPsychosocial treatment plus Suboxone pharmacotherapy

Optimizing Outcomes Using Suboxone for Opiate Dependence

Start: Sep 2006Est. completion: Dec 2012202 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.